nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—Digestion impaired—Methoxsalen—psoriasis	0.0441	0.0509	CcSEcCtD
Methamphetamine—Digestion impaired—Hydroxyurea—psoriasis	0.0275	0.0317	CcSEcCtD
Methamphetamine—Psychotic disorder—Calcitriol—psoriasis	0.0186	0.0215	CcSEcCtD
Methamphetamine—Digestion impaired—Cyclosporine—psoriasis	0.0186	0.0215	CcSEcCtD
Methamphetamine—Hypersensitivity—Calcipotriol—psoriasis	0.0174	0.0201	CcSEcCtD
Methamphetamine—Erectile dysfunction—Acitretin—psoriasis	0.0135	0.0156	CcSEcCtD
Methamphetamine—Psychotic disorder—Mycophenolic acid—psoriasis	0.0109	0.0126	CcSEcCtD
Methamphetamine—Hypersensitivity—Clobetasol propionate—psoriasis	0.0109	0.0126	CcSEcCtD
Methamphetamine—Urticaria—Beclomethasone—psoriasis	0.0107	0.0123	CcSEcCtD
Methamphetamine—Agitation—Calcitriol—psoriasis	0.0106	0.0122	CcSEcCtD
Methamphetamine—Hypersensitivity—Fluocinonide—psoriasis	0.00982	0.0113	CcSEcCtD
Methamphetamine—Euphoric mood—Prednisolone—psoriasis	0.00973	0.0112	CcSEcCtD
Methamphetamine—Insomnia—Methoxsalen—psoriasis	0.00952	0.011	CcSEcCtD
Methamphetamine—Euphoric mood—Hydrocortisone—psoriasis	0.0095	0.011	CcSEcCtD
Methamphetamine—Dyspepsia—Methoxsalen—psoriasis	0.00926	0.0107	CcSEcCtD
Methamphetamine—Headache—Clobetasol propionate—psoriasis	0.00926	0.0107	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Methoxsalen—psoriasis	0.00908	0.0105	CcSEcCtD
Methamphetamine—Euphoric mood—Triamcinolone—psoriasis	0.00894	0.0103	CcSEcCtD
Methamphetamine—Dizziness—Beclomethasone—psoriasis	0.0089	0.0103	CcSEcCtD
Methamphetamine—Erectile dysfunction—Mycophenolic acid—psoriasis	0.00889	0.0103	CcSEcCtD
Methamphetamine—Dizziness—Fluocinonide—psoriasis	0.00882	0.0102	CcSEcCtD
Methamphetamine—Psychotic disorder—Mycophenolate mofetil—psoriasis	0.0086	0.00993	CcSEcCtD
Methamphetamine—Insomnia—Calcitriol—psoriasis	0.00848	0.0098	CcSEcCtD
Methamphetamine—Headache—Beclomethasone—psoriasis	0.00843	0.00973	CcSEcCtD
Methamphetamine—Urticaria—Methoxsalen—psoriasis	0.00836	0.00965	CcSEcCtD
Methamphetamine—Headache—Fluocinonide—psoriasis	0.00835	0.00964	CcSEcCtD
Methamphetamine—Euphoric mood—Betamethasone—psoriasis	0.00812	0.00937	CcSEcCtD
Methamphetamine—Euphoric mood—Dexamethasone—psoriasis	0.00812	0.00937	CcSEcCtD
Methamphetamine—Constipation—Calcitriol—psoriasis	0.00802	0.00926	CcSEcCtD
Methamphetamine—Psychotic disorder—Hydrocortisone—psoriasis	0.00784	0.00905	CcSEcCtD
Methamphetamine—Hypersensitivity—Methoxsalen—psoriasis	0.00775	0.00895	CcSEcCtD
Methamphetamine—Insomnia—Acitretin—psoriasis	0.00755	0.00871	CcSEcCtD
Methamphetamine—Urticaria—Calcitriol—psoriasis	0.00745	0.0086	CcSEcCtD
Methamphetamine—Dyspepsia—Acitretin—psoriasis	0.00734	0.00848	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Acitretin—psoriasis	0.0072	0.00832	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.00718	0.00829	CcSEcCtD
Methamphetamine—Constipation—Acitretin—psoriasis	0.00713	0.00824	CcSEcCtD
Methamphetamine—Euphoric mood—Prednisone—psoriasis	0.00707	0.00816	CcSEcCtD
Methamphetamine—Erectile dysfunction—Mycophenolate mofetil—psoriasis	0.00701	0.0081	CcSEcCtD
Methamphetamine—Dizziness—Methoxsalen—psoriasis	0.00696	0.00803	CcSEcCtD
Methamphetamine—Hypersensitivity—Calcitriol—psoriasis	0.00691	0.00798	CcSEcCtD
Methamphetamine—Psychotic disorder—Betamethasone—psoriasis	0.0067	0.00773	CcSEcCtD
Methamphetamine—Psychotic disorder—Dexamethasone—psoriasis	0.0067	0.00773	CcSEcCtD
Methamphetamine—Urticaria—Acitretin—psoriasis	0.00663	0.00765	CcSEcCtD
Methamphetamine—Headache—Methoxsalen—psoriasis	0.00659	0.00761	CcSEcCtD
Methamphetamine—Diarrhoea—Calcitriol—psoriasis	0.00642	0.00741	CcSEcCtD
Methamphetamine—Tremor—Mycophenolic acid—psoriasis	0.0063	0.00727	CcSEcCtD
Methamphetamine—Agitation—Mycophenolic acid—psoriasis	0.00618	0.00713	CcSEcCtD
Methamphetamine—Hypersensitivity—Acitretin—psoriasis	0.00615	0.0071	CcSEcCtD
Methamphetamine—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00613	0.00708	CcSEcCtD
Methamphetamine—Palpitations—Mycophenolic acid—psoriasis	0.00594	0.00686	CcSEcCtD
Methamphetamine—Headache—Calcitriol—psoriasis	0.00588	0.00678	CcSEcCtD
Methamphetamine—Psychotic disorder—Prednisone—psoriasis	0.00583	0.00673	CcSEcCtD
Methamphetamine—Dyspepsia—Hydroxyurea—psoriasis	0.00577	0.00666	CcSEcCtD
Methamphetamine—Diarrhoea—Acitretin—psoriasis	0.00571	0.00659	CcSEcCtD
Methamphetamine—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00569	0.00657	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00566	0.00653	CcSEcCtD
Methamphetamine—Constipation—Hydroxyurea—psoriasis	0.0056	0.00647	CcSEcCtD
Methamphetamine—Dizziness—Acitretin—psoriasis	0.00552	0.00637	CcSEcCtD
Methamphetamine—Dizziness—Fluocinolone Acetonide—psoriasis	0.0055	0.00635	CcSEcCtD
Methamphetamine—Tachycardia—Mycophenolic acid—psoriasis	0.00535	0.00618	CcSEcCtD
Methamphetamine—Headache—Acitretin—psoriasis	0.00523	0.00604	CcSEcCtD
Methamphetamine—Headache—Fluocinolone Acetonide—psoriasis	0.00521	0.00602	CcSEcCtD
Methamphetamine—Tremor—Cyclosporine—psoriasis	0.0051	0.00588	CcSEcCtD
Methamphetamine—Agitation—Cyclosporine—psoriasis	0.005	0.00577	CcSEcCtD
Methamphetamine—Tremor—Mycophenolate mofetil—psoriasis	0.00497	0.00574	CcSEcCtD
Methamphetamine—Insomnia—Mycophenolic acid—psoriasis	0.00496	0.00573	CcSEcCtD
Methamphetamine—Agitation—Mycophenolate mofetil—psoriasis	0.00488	0.00563	CcSEcCtD
Methamphetamine—Dyspepsia—Mycophenolic acid—psoriasis	0.00483	0.00558	CcSEcCtD
Methamphetamine—Hypersensitivity—Hydroxyurea—psoriasis	0.00483	0.00557	CcSEcCtD
Methamphetamine—Erectile dysfunction—Prednisone—psoriasis	0.00475	0.00549	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00474	0.00547	CcSEcCtD
Methamphetamine—Constipation—Mycophenolic acid—psoriasis	0.00469	0.00542	CcSEcCtD
Methamphetamine—Palpitations—Mycophenolate mofetil—psoriasis	0.00469	0.00541	CcSEcCtD
Methamphetamine—Diarrhoea—Hydroxyurea—psoriasis	0.00448	0.00518	CcSEcCtD
Methamphetamine—Dizziness—Hydroxyurea—psoriasis	0.00433	0.005	CcSEcCtD
Methamphetamine—Tachycardia—Mycophenolate mofetil—psoriasis	0.00423	0.00488	CcSEcCtD
Methamphetamine—Headache—Hydroxyurea—psoriasis	0.0041	0.00474	CcSEcCtD
Methamphetamine—Insomnia—Cyclosporine—psoriasis	0.00401	0.00464	CcSEcCtD
Methamphetamine—Erectile dysfunction—Methotrexate—psoriasis	0.00397	0.00459	CcSEcCtD
Methamphetamine—Tachycardia—Prednisolone—psoriasis	0.00394	0.00455	CcSEcCtD
Methamphetamine—Insomnia—Mycophenolate mofetil—psoriasis	0.00392	0.00452	CcSEcCtD
Methamphetamine—Dyspepsia—Cyclosporine—psoriasis	0.00391	0.00451	CcSEcCtD
Methamphetamine—Tachycardia—Hydrocortisone—psoriasis	0.00385	0.00445	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00383	0.00442	CcSEcCtD
Methamphetamine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00382	0.0294	CbGpPWpGaD
Methamphetamine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.00381	0.0044	CcSEcCtD
Methamphetamine—Constipation—Cyclosporine—psoriasis	0.0038	0.00438	CcSEcCtD
Methamphetamine—Diarrhoea—Mycophenolic acid—psoriasis	0.00375	0.00433	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00374	0.00432	CcSEcCtD
Methamphetamine—Constipation—Mycophenolate mofetil—psoriasis	0.0037	0.00428	CcSEcCtD
Methamphetamine—Insomnia—Prednisolone—psoriasis	0.00365	0.00422	CcSEcCtD
Methamphetamine—Dizziness—Mycophenolic acid—psoriasis	0.00363	0.00419	CcSEcCtD
Methamphetamine—Tachycardia—Triamcinolone—psoriasis	0.00362	0.00419	CcSEcCtD
Methamphetamine—Insomnia—Hydrocortisone—psoriasis	0.00357	0.00412	CcSEcCtD
Methamphetamine—Urticaria—Cyclosporine—psoriasis	0.00353	0.00407	CcSEcCtD
Methamphetamine—Dyspepsia—Hydrocortisone—psoriasis	0.00347	0.00401	CcSEcCtD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00344	0.0265	CbGpPWpGaD
Methamphetamine—Urticaria—Mycophenolate mofetil—psoriasis	0.00344	0.00397	CcSEcCtD
Methamphetamine—Headache—Mycophenolic acid—psoriasis	0.00344	0.00397	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00341	0.00393	CcSEcCtD
Methamphetamine—Insomnia—Triamcinolone—psoriasis	0.00336	0.00388	CcSEcCtD
Methamphetamine—Agitation—Prednisone—psoriasis	0.0033	0.00382	CcSEcCtD
Methamphetamine—Tachycardia—Dexamethasone—psoriasis	0.00329	0.0038	CcSEcCtD
Methamphetamine—Tachycardia—Betamethasone—psoriasis	0.00329	0.0038	CcSEcCtD
Methamphetamine—Hypersensitivity—Cyclosporine—psoriasis	0.00327	0.00378	CcSEcCtD
Methamphetamine—Dyspepsia—Triamcinolone—psoriasis	0.00327	0.00378	CcSEcCtD
Methamphetamine—Urticaria—Prednisolone—psoriasis	0.00321	0.00371	CcSEcCtD
Methamphetamine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00319	0.00368	CcSEcCtD
Methamphetamine—Urticaria—Hydrocortisone—psoriasis	0.00313	0.00362	CcSEcCtD
Methamphetamine—Insomnia—Dexamethasone—psoriasis	0.00305	0.00352	CcSEcCtD
Methamphetamine—Insomnia—Betamethasone—psoriasis	0.00305	0.00352	CcSEcCtD
Methamphetamine—Diarrhoea—Cyclosporine—psoriasis	0.00304	0.00351	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisolone—psoriasis	0.00298	0.00344	CcSEcCtD
Methamphetamine—Dyspepsia—Betamethasone—psoriasis	0.00297	0.00343	CcSEcCtD
Methamphetamine—Dyspepsia—Dexamethasone—psoriasis	0.00297	0.00343	CcSEcCtD
Methamphetamine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00296	0.00342	CcSEcCtD
Methamphetamine—MAOA—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00296	0.0228	CbGpPWpGaD
Methamphetamine—Urticaria—Triamcinolone—psoriasis	0.00295	0.00341	CcSEcCtD
Methamphetamine—Dizziness—Cyclosporine—psoriasis	0.00294	0.00339	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Betamethasone—psoriasis	0.00291	0.00336	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00291	0.00336	CcSEcCtD
Methamphetamine—Hypersensitivity—Hydrocortisone—psoriasis	0.00291	0.00336	CcSEcCtD
Methamphetamine—Tachycardia—Prednisone—psoriasis	0.00286	0.00331	CcSEcCtD
Methamphetamine—Dizziness—Mycophenolate mofetil—psoriasis	0.00286	0.00331	CcSEcCtD
Methamphetamine—Headache—Cyclosporine—psoriasis	0.00278	0.00321	CcSEcCtD
Methamphetamine—Hypersensitivity—Triamcinolone—psoriasis	0.00274	0.00316	CcSEcCtD
Methamphetamine—Headache—Mycophenolate mofetil—psoriasis	0.00271	0.00313	CcSEcCtD
Methamphetamine—Diarrhoea—Hydrocortisone—psoriasis	0.0027	0.00312	CcSEcCtD
Methamphetamine—Urticaria—Dexamethasone—psoriasis	0.00268	0.00309	CcSEcCtD
Methamphetamine—Urticaria—Betamethasone—psoriasis	0.00268	0.00309	CcSEcCtD
Methamphetamine—Dizziness—Prednisolone—psoriasis	0.00267	0.00308	CcSEcCtD
Methamphetamine—Insomnia—Prednisone—psoriasis	0.00265	0.00307	CcSEcCtD
Methamphetamine—TAAR1—GPCR ligand binding—HCAR2—psoriasis	0.00262	0.0202	CbGpPWpGaD
Methamphetamine—Dizziness—Hydrocortisone—psoriasis	0.00261	0.00301	CcSEcCtD
Methamphetamine—Dyspepsia—Prednisone—psoriasis	0.00258	0.00298	CcSEcCtD
Methamphetamine—Headache—Prednisolone—psoriasis	0.00253	0.00292	CcSEcCtD
Methamphetamine—Constipation—Prednisone—psoriasis	0.00251	0.0029	CcSEcCtD
Methamphetamine—MAOB—Biological oxidations—CYP2S1—psoriasis	0.0025	0.0193	CbGpPWpGaD
Methamphetamine—Headache—Hydrocortisone—psoriasis	0.00247	0.00285	CcSEcCtD
Methamphetamine—Dizziness—Triamcinolone—psoriasis	0.00246	0.00284	CcSEcCtD
Methamphetamine—Urticaria—Prednisone—psoriasis	0.00233	0.00269	CcSEcCtD
Methamphetamine—Headache—Triamcinolone—psoriasis	0.00233	0.00269	CcSEcCtD
Methamphetamine—Diarrhoea—Betamethasone—psoriasis	0.00231	0.00266	CcSEcCtD
Methamphetamine—Diarrhoea—Dexamethasone—psoriasis	0.00231	0.00266	CcSEcCtD
Methamphetamine—Dizziness—Dexamethasone—psoriasis	0.00223	0.00257	CcSEcCtD
Methamphetamine—Dizziness—Betamethasone—psoriasis	0.00223	0.00257	CcSEcCtD
Methamphetamine—Insomnia—Methotrexate—psoriasis	0.00222	0.00256	CcSEcCtD
Methamphetamine—SLC18A1—SLC-mediated transmembrane transport—CP—psoriasis	0.00221	0.017	CbGpPWpGaD
Methamphetamine—Hypersensitivity—Prednisone—psoriasis	0.00216	0.0025	CcSEcCtD
Methamphetamine—MAOB—Tryptophan metabolism—CAT—psoriasis	0.00216	0.0166	CbGpPWpGaD
Methamphetamine—Dyspepsia—Methotrexate—psoriasis	0.00216	0.00249	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Methotrexate—psoriasis	0.00212	0.00245	CcSEcCtD
Methamphetamine—Headache—Betamethasone—psoriasis	0.00211	0.00244	CcSEcCtD
Methamphetamine—Headache—Dexamethasone—psoriasis	0.00211	0.00244	CcSEcCtD
Methamphetamine—Pseudoephedrine—TNF—psoriasis	0.00205	0.505	CrCbGaD
Methamphetamine—Nateglinide—PPARG—psoriasis	0.00201	0.495	CrCbGaD
Methamphetamine—Diarrhoea—Prednisone—psoriasis	0.00201	0.00232	CcSEcCtD
Methamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00198	0.0153	CbGpPWpGaD
Methamphetamine—Urticaria—Methotrexate—psoriasis	0.00195	0.00225	CcSEcCtD
Methamphetamine—Dizziness—Prednisone—psoriasis	0.00194	0.00224	CcSEcCtD
Methamphetamine—MAOA—Oxidative Stress—CAT—psoriasis	0.00191	0.0147	CbGpPWpGaD
Methamphetamine—Headache—Prednisone—psoriasis	0.00184	0.00212	CcSEcCtD
Methamphetamine—Hypersensitivity—Methotrexate—psoriasis	0.00181	0.00209	CcSEcCtD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00179	0.0138	CbGpPWpGaD
Methamphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00171	0.0132	CbGpPWpGaD
Methamphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00171	0.0131	CbGpPWpGaD
Methamphetamine—Diarrhoea—Methotrexate—psoriasis	0.00168	0.00194	CcSEcCtD
Methamphetamine—Dizziness—Methotrexate—psoriasis	0.00162	0.00187	CcSEcCtD
Methamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00159	0.0122	CbGpPWpGaD
Methamphetamine—MAOA—Biological oxidations—CYP2S1—psoriasis	0.00157	0.0121	CbGpPWpGaD
Methamphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00157	0.0121	CbGpPWpGaD
Methamphetamine—Headache—Methotrexate—psoriasis	0.00154	0.00177	CcSEcCtD
Methamphetamine—MAOA—Melatonin metabolism and effects—APOE—psoriasis	0.00152	0.0117	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—HCAR2—psoriasis	0.00148	0.0114	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—CCL20—psoriasis	0.00136	0.0105	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HCAR2—psoriasis	0.00135	0.0104	CbGpPWpGaD
Methamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00133	0.0103	CbGpPWpGaD
Methamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00129	0.0099	CbGpPWpGaD
Methamphetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—psoriasis	0.00123	0.0095	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—HCAR2—psoriasis	0.00119	0.00917	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00119	0.00916	CbGpPWpGaD
Methamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00118	0.00909	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—CP—psoriasis	0.00112	0.00863	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—HCAR2—psoriasis	0.00111	0.00856	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.00107	0.00823	CbGpPWpGaD
Methamphetamine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.00107	0.00821	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SERPINB8—psoriasis	0.00106	0.00819	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SERPINB8—psoriasis	0.000994	0.00765	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000975	0.0075	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000947	0.00729	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000939	0.00723	CbGpPWpGaD
Methamphetamine—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000917	0.00706	CbGpPWpGaD
Methamphetamine—MAOA—Melatonin metabolism and effects—NFKB1—psoriasis	0.000905	0.00697	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—HCAR2—psoriasis	0.000904	0.00696	CbGpPWpGaD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000901	0.00693	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000885	0.00681	CbGpPWpGaD
Methamphetamine—MAOA—Oxidative Stress—NFKB1—psoriasis	0.000881	0.00678	CbGpPWpGaD
Methamphetamine—SLC6A3—NRF2 pathway—TGFA—psoriasis	0.000813	0.00625	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SERPINB8—psoriasis	0.000808	0.00622	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HCAR2—psoriasis	0.000795	0.00612	CbGpPWpGaD
Methamphetamine—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000794	0.00611	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000779	0.00599	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000776	0.00597	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL13—psoriasis	0.00077	0.00593	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CCL20—psoriasis	0.000769	0.00592	CbGpPWpGaD
Methamphetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000736	0.00566	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HCAR2—psoriasis	0.000721	0.00555	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000719	0.00553	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CCL20—psoriasis	0.000699	0.00538	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TAGAP—psoriasis	0.000689	0.0053	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000684	0.00526	CbGpPWpGaD
Methamphetamine—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000683	0.00526	CbGpPWpGaD
Methamphetamine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000674	0.00519	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HCAR2—psoriasis	0.000674	0.00518	CbGpPWpGaD
Methamphetamine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000663	0.0051	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CCL20—psoriasis	0.000619	0.00476	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000606	0.00466	CbGpPWpGaD
Methamphetamine—SLC6A3—Monoamine Transport—TNF—psoriasis	0.000605	0.00466	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000588	0.00452	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CCL20—psoriasis	0.000578	0.00445	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HCAR2—psoriasis	0.000547	0.00421	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000537	0.00413	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—NDUFA5—psoriasis	0.000503	0.00387	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000492	0.00379	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000483	0.00372	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL10—psoriasis	0.000482	0.00371	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CCL20—psoriasis	0.000469	0.00361	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00046	0.00354	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—CP—psoriasis	0.000458	0.00352	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000437	0.00336	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CYP2S1—psoriasis	0.000428	0.00329	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NDUFA5—psoriasis	0.000426	0.00328	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCL20—psoriasis	0.000413	0.00318	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HCAR2—psoriasis	0.000408	0.00314	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—CP—psoriasis	0.000396	0.00305	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	0.000395	0.00304	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	0.000394	0.00304	CbGpPWpGaD
Methamphetamine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000394	0.00303	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HCAR2—psoriasis	0.000381	0.00293	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—CARM1—psoriasis	0.000378	0.00291	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	0.000376	0.0029	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCL20—psoriasis	0.000375	0.00288	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000373	0.00287	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HCAR2—psoriasis	0.00037	0.00285	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	0.000368	0.00283	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—CXCL8—psoriasis	0.000368	0.00283	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP2S1—psoriasis	0.000362	0.00279	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCL20—psoriasis	0.00035	0.00269	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HCAR2—psoriasis	0.000346	0.00266	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	0.000344	0.00265	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000321	0.00247	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NDUFA5—psoriasis	0.000316	0.00243	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HCAR2—psoriasis	0.000309	0.00238	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ITGAL—psoriasis	0.000309	0.00238	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	0.000308	0.00237	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	0.000299	0.0023	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000294	0.00226	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ITGAL—psoriasis	0.000289	0.00222	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000288	0.00221	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL20—psoriasis	0.000284	0.00219	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HCAR2—psoriasis	0.000281	0.00216	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	0.000273	0.0021	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP2S1—psoriasis	0.000269	0.00207	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000263	0.00203	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000261	0.00201	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	0.00026	0.002	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NDUFA5—psoriasis	0.00026	0.002	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—JUN—psoriasis	0.000245	0.00188	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	0.000244	0.00188	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000236	0.00181	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ITGAL—psoriasis	0.000235	0.00181	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SOCS1—psoriasis	0.000227	0.00175	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	0.000224	0.00172	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP2S1—psoriasis	0.000221	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HCAR2—psoriasis	0.000219	0.00168	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TYK2—psoriasis	0.000217	0.00167	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000214	0.00165	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCL20—psoriasis	0.000212	0.00163	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NDUFA5—psoriasis	0.000211	0.00162	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CARM1—psoriasis	0.000209	0.00161	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CXCL8—psoriasis	0.000208	0.0016	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HCAR2—psoriasis	0.000204	0.00157	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCL20—psoriasis	0.000198	0.00152	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL20—psoriasis	0.000192	0.00148	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TAGAP—psoriasis	0.00019	0.00146	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CXCL8—psoriasis	0.000189	0.00145	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—psoriasis	0.000183	0.00141	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	0.00018	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL20—psoriasis	0.00018	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP2S1—psoriasis	0.000179	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TAGAP—psoriasis	0.000177	0.00136	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CARM1—psoriasis	0.000177	0.00136	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—LEP—psoriasis	0.000168	0.00129	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—APOE—psoriasis	0.000168	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CXCL8—psoriasis	0.000167	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HCAR2—psoriasis	0.000166	0.00128	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	0.000161	0.00124	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCL20—psoriasis	0.000161	0.00124	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NFKBIA—psoriasis	0.000156	0.0012	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCL8—psoriasis	0.000156	0.0012	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL6—psoriasis	0.000148	0.00114	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	0.000147	0.00113	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL20—psoriasis	0.000146	0.00112	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TAGAP—psoriasis	0.000144	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000143	0.0011	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NDUFA5—psoriasis	0.000138	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000133	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000133	0.00102	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CARM1—psoriasis	0.000131	0.00101	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CAT—psoriasis	0.000129	0.000989	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TYK2—psoriasis	0.000128	0.000985	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—NOS2—psoriasis	0.000127	0.000976	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL8—psoriasis	0.000127	0.000976	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000124	0.000955	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—NOS2—psoriasis	0.000118	0.000912	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP2S1—psoriasis	0.000117	0.0009	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL20—psoriasis	0.000114	0.000874	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL8—psoriasis	0.000111	0.000858	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CAT—psoriasis	0.000109	0.000837	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000108	0.000832	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CARM1—psoriasis	0.000108	0.00083	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL20—psoriasis	0.000106	0.000816	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—psoriasis	0.000106	0.000816	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—JUN—psoriasis	0.000104	0.000797	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL8—psoriasis	0.000101	0.000779	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000101	0.000776	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—APOE—psoriasis	9.99e-05	0.000769	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NFKB1—psoriasis	9.97e-05	0.000768	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—NOS2—psoriasis	9.62e-05	0.000741	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL8—psoriasis	9.45e-05	0.000727	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VEGFA—psoriasis	9.05e-05	0.000697	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—STAT3—psoriasis	8.96e-05	0.00069	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CARM1—psoriasis	8.76e-05	0.000674	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PPARG—psoriasis	8.7e-05	0.00067	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL20—psoriasis	8.62e-05	0.000663	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—APOE—psoriasis	8.45e-05	0.00065	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CAT—psoriasis	8.07e-05	0.000621	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	7.68e-05	0.000591	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PPARG—psoriasis	7.36e-05	0.000566	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VEGFA—psoriasis	7.35e-05	0.000565	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—psoriasis	6.86e-05	0.000528	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—psoriasis	6.84e-05	0.000526	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CAT—psoriasis	6.64e-05	0.000511	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—APOE—psoriasis	6.27e-05	0.000482	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—psoriasis	6.26e-05	0.000482	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SOCS1—psoriasis	6.25e-05	0.000481	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TYK2—psoriasis	5.96e-05	0.000459	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SOCS1—psoriasis	5.84e-05	0.00045	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	5.72e-05	0.00044	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CARM1—psoriasis	5.71e-05	0.000439	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—psoriasis	5.57e-05	0.000429	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TYK2—psoriasis	5.57e-05	0.000429	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—psoriasis	5.55e-05	0.000427	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PPARG—psoriasis	5.46e-05	0.00042	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CAT—psoriasis	5.39e-05	0.000415	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	5.34e-05	0.000411	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	5.19e-05	0.0004	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—psoriasis	5.19e-05	0.000399	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—psoriasis	5.16e-05	0.000397	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	4.85e-05	0.000373	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SOCS1—psoriasis	4.74e-05	0.000365	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LEP—psoriasis	4.62e-05	0.000355	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—psoriasis	4.62e-05	0.000355	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TYK2—psoriasis	4.52e-05	0.000348	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARG—psoriasis	4.49e-05	0.000346	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	4.34e-05	0.000334	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—psoriasis	4.31e-05	0.000332	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—psoriasis	4.31e-05	0.000332	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	4.3e-05	0.000331	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—psoriasis	4.21e-05	0.000324	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—psoriasis	4.19e-05	0.000322	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	4.02e-05	0.000309	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	3.94e-05	0.000303	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARG—psoriasis	3.65e-05	0.000281	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TYK2—psoriasis	3.52e-05	0.000271	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAT—psoriasis	3.51e-05	0.00027	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—psoriasis	3.5e-05	0.000269	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—psoriasis	3.5e-05	0.000269	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TYK2—psoriasis	3.29e-05	0.000253	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	3.26e-05	0.000251	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—psoriasis	3.07e-05	0.000236	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—psoriasis	2.92e-05	0.000224	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—psoriasis	2.86e-05	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JUN—psoriasis	2.85e-05	0.000219	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKB1—psoriasis	2.74e-05	0.000211	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—psoriasis	2.73e-05	0.00021	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—psoriasis	2.72e-05	0.00021	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TYK2—psoriasis	2.67e-05	0.000206	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JUN—psoriasis	2.66e-05	0.000205	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKB1—psoriasis	2.56e-05	0.000197	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—psoriasis	2.49e-05	0.000192	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—psoriasis	2.47e-05	0.00019	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARG—psoriasis	2.38e-05	0.000183	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—psoriasis	2.33e-05	0.000179	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—psoriasis	2.33e-05	0.000179	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—psoriasis	2.3e-05	0.000177	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—psoriasis	2.21e-05	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JUN—psoriasis	2.16e-05	0.000166	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKB1—psoriasis	2.08e-05	0.00016	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—psoriasis	1.89e-05	0.000145	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—psoriasis	1.88e-05	0.000145	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—psoriasis	1.87e-05	0.000144	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—psoriasis	1.76e-05	0.000135	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—psoriasis	1.72e-05	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—psoriasis	1.61e-05	0.000124	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—psoriasis	1.43e-05	0.00011	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—psoriasis	1.31e-05	0.000101	CbGpPWpGaD
